Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Esophageal Squamous Cell Carcinoma
Related studies linked through entity extraction aliases.
Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- NA
Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study
- Status
- UNKNOWN
- Phase
- N/A
PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
- Status
- COMPLETED
- Phase
- N/A
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
- Status
- UNKNOWN
- Phase
- PHASE2
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody
- Status
- UNKNOWN
- Phase
- PHASE2
Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- NA
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- NA
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)
- Status
- UNKNOWN
- Phase
- PHASE2
The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy
- Status
- COMPLETED
- Phase
- NA
Precisely Estimation of the Prognostic Value of Lymph Node in ESCC
- Status
- COMPLETED
- Phase
- N/A
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCC
- Status
- UNKNOWN
- Phase
- N/A
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2